4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for use in gene therapy products. Financial details were not disclosed.
“We are thrilled to enter into this collaboration with Roche, a global leader in research-focused healthcare,” said Dr. David Kirn, co-founder and CEO of 4DMT. “We believe that great synergies can be achieved by combining our AAV gene therapy platform discovery with Roche’s expertise in novel biologics. Together we can potentially develop transformative new gene therapies. As the fourth collaboration to be announced by 4D over the last year, we are realizing our vision of creating a robust product pipeline with our partners.”
